Clinical Trial Update: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in relapsed/refractory follicular lymphoma or diffuse lar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Obinutuzumab (obinutuzumab)
• Rituximab (rituximab)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-14